Dr. Jennifer Zelovitzky (pictured above) is the clinical director of women’s health and vitality at Medcan, and she also leads the new perimenopause and menopause program. Here, she joins Marisa Ciarlitto to chat about the questions that she gets asked most, how she helped some of her clients get through common problems, and how you can get the most benefit out of your next appointment with your doctor.

Last year, Medcan director of weight management Dr. David Macklin (pictured above) predicted the diabetes medication semaglutide would be a game changer for those seeking help to lose weight. So we invited back Dr. Macklin to get his perspective on the medication, now that it’s actually on the market and being used by hundreds of thousands of people across North America. Joined by Medcan CMO Dr. Peter Nord, Dr. Macklin explains semaglutide’s benefits, side effects and costs — and describes what’s different about Medcan’s approach to weight management in the semaglutide era.

Dr. Jennifer Zelovitzky is the clinical director of women’s health and vitality at Medcan and leads the new perimenopause and menopause program. She’s a certified menopause practitioner and an advocate for the benefits of hormone replacement therapy. Here, she joins Director of Clinical Innovation Allison Hazell to talk about menopause misconceptions, the education gap that exists around women’s health—and how Medcan’s new program aims to empower women with knowledge.